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Background: Sentinel lymph node biopsy (SLNB) demonstrates promising results as an accurate alter-
native to axillary lymph node dissection in patients with locally advanced breast cancer after neo-
adjuvant chemotherapy (NAC). However and in the view of the insufﬁcient data on women with
inﬂammatory breast cancer (IBC), SLNB is not recommended in this situation. The current study assessed
identiﬁcation and false-negative rates of SLNB after NAC for patients with IBC.
Methods: Between 2006 and 2009, twenty consecutive patients with clinically negative nodes after NAC
for IBC (T4d) and who underwent SLNB and axillary lymph node dissection (levels I and II) by the same
operator were assessed. Intraoperative Sentinel lymph node biopsy was performed with patent blue dye
injections.
Results: The SLN could be identiﬁed in 16 of 20 patients (identiﬁcation rate, 80%), the median of SLN
removed per patient was 2 (range 1–3); nine (56%) had positive SLNB, and in 2 of those 9 patients (22%),
the SLN was the only positive node with otherwise negative axillary nodes. Two (18%) patients’ SLNB
were false negative.
Conclusions: The SLN identiﬁcation and false-negative rates after NAC for IBC were unacceptably high
and based on the current ﬁndings, SLNB without systematic axillary lymph node dissection is unsuitable
in this patient population.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Inﬂammatory breast cancer (IBC) is the most aggressive form of
breast cancer,1 the diagnosis relies on clinical features and reported
incidence in western countries vary from 1 to 6% of all breast
cancers.1–5 Incidence in Tunisia is estimated around 7%.6 Neo-
adjuvant chemotherapy (NAC) is indicated to locally downstage
patients and allows for subsequent surgery.7
The efﬁcacy and utility of NAC for locally advanced breast cancer
(LABC) is demonstrated,8,9 it may result in tumor downstaging and
the axillae of these patients can be rendered pathologicallyammatory breast cancer; IR,
cancer; NAC, Neoadjuvant
tinel lymph node biopsy.
ciates Ltd. Published by Elsevier Ltnegative.9,10 The latter group of patients might therefore theoreti-
cally not require an axillary lymph node clearance and be candidate
for sentinel lymph node biopsy (SLNB). Published data for SLNB in
non inﬂammatory locally advanced breast cancer are encouraging
and future targeted speciﬁc NAC for IBC will further likely increase
the sterilization rate of axillary lymph nodes.11
It has been suggested that because of cancer inﬁltration,
lymphatic channels may be occluded or disrupted impeding the
ﬂow of the dye12 and decreasing the accuracy of SLNB technique. To
date scarce data exist regarding the accuracy of SLNB in IBC; to the
best of our knowledge, only one study including 8 cases13 examined
the feasibility and accuracy of this technique in this context. In the
view of paucity of data, SLNB is not recommended for this patient
population.12,14
We therefore aimed to assess the identiﬁcation rate (IR) and
false-negative rate (FNR) of SLNB in a subgroup of patients with IBC
treated with NAC.d. All rights reserved.
Table 2
Status of sentinel and non sentinel nodes in patients in whom SLN was identiﬁed
(n¼ 16).
Axillary dissection
Positive Negative Total
Sentinel nodes
Positive 7 2 (SLN was the only positive node) 9
Negative 2a 5 7
Total 9 7 16
SLN: sentinel lymph node biopsy.
a False-negative rate (18.2%; 2/2þ 9).
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Between 2006 and 2009, data of all non pregnant patients who
received NAC for histologically proven inﬁltrating carcinoma of the
breast clinically classiﬁed according to current recommendations as
inﬂammatory1,15 by at least two experienced clinicians (T4d) and
who underwent an SLNB during the deﬁnitive modiﬁed radical
mastectomy with axillary lymph node clearance were reviewed.
Procedures were performed at the O&G department, Farhat Hached
university teaching hospital – Sousse, Tunisia by the same operator
(SH) who achieved desired benchmarks (>90% IR, and<5% FNR; 40
patients).
Before NAC, patients had clinical and radiographic assessment
(diagnostic mammography and ultrasound, chest X-ray, liver
imaging, bone scan and biopsies). Chemotherapy cycles were
administrated at the oncology department of the same institution
and patients were reviewed by a multidisciplinary team. Three
weeks after completion of NAC, only patients without palpably
suspicious nodes underwent the procedure after informed consent.
Under general anesthesia, 2 ml of patent blue-V dye (Bleu Pat-
ente´ V 2.5% sodique, Laboratoire Guerbet, Aulney-Sous-Bois, France)
were injected around the primary tumor or circumferentially
around the areola – in case of impalpable tumor or complete clin-
ical response (4 injections of 0.5 ml each) – this was followed by
massage of the breast for 10 min. Axillary incision was then per-
formed and lymphatic vessels were identiﬁed and followed to the
node that drained the blue dye. The sentinel node(s) were identi-
ﬁed as being blue, removed separately and sent to pathology. After
SLNB biopsy, mastectomy and axillary dissection (levels I and II)
were fully performed.
Sentinel lymph nodes (SLN) were ﬁxed in formalin, embedded
in parafﬁn, processed for permanent sectioning and stained by
H&E. If negative, sentinel nodes were evaluated for the presence of
micrometastases by immunohistochemistry.
At our institution SLNB before systematic axillary clearance is
performed in an institutional review board approved protocol and
widely performed in an effort to improve the accuracy of pathologic
staging by identifying lymph node(s) that are most likely meta-
static. The aims of the present study were to assess the sentinel
node identiﬁcation rate (IR) and false-negative rate (FNR). A false-
negative SLNB was deﬁned as a patient who had a successful SLN
identiﬁcation and a negative SLN (H&E and immunohistochem-
istry) with disease detected in one or more non-SLN.3. Results
During this period, a total of 20 patients with IBC underwent
SLNB after NAC using the above mentioned technique. Median age
at the time of diagnosis was 49 years (range 26–66 years), three
(15%) patients had non palpable tumors and 13 (65%) had palpable
axillary lymph nodes (N1 or N2). Tumor was localized in the
external quadrant in 10 cases (50%), mean size at diagnosis was
6.9 2.2 cm. Core needle biopsy was obtained in 15 cases (75%) and
incisional biopsy in the others patients, no excisional biopsy wasTable 1
Characteristics of patients with failed sentinel lymph node identiﬁcation after NAC.
Histology Initial tumor size No. of NAC cycles Preoper
tumor s
1 Invasive ductal 4 4 4
2 Invasive ductal 5 4 4
3 Invasiveþ in situ ductal 5 5 4
4 Invasiveþ in situ ductal 0 4
NAC: neoadjuvant chemotherapy.performed. Pathology revealed invasive ductal carcinoma in 18
specimens (90%) with an intra ductal component in 6 cases.
Estrogen receptor status was positive in 3 (15%) patients.
All patients were treated with preoperative combination of
ﬂuorouracil, epirubicin and cyclophosphamide (FEC). Eighteen
patients (90%) received 4 cycles and 2 patients (10%) 5 cycles. Mean
residual size was 4.51.3 cm; complete clinical response was
achieved in 5 cases (25%); in all other cases clinical response was
incomplete; no patient exhibited tumor growth during NAC. A
complete clinical axilla response was obtained in all cases. (inclu-
sion criteria).
The SLNBwas detected in 16 cases (IR¼ 80.0%) (Table 1), and the
false-negative rate was 18.2% (2/11) (Tables 2 and 3). The median of
SLN removed per patient was 2 (range 1–3) and in two cases (13.3%)
it was the only positive node. All SLN metastasis were detected on
H&E staining, further pathologic evaluation of the immunohisto-
chemical negative SLN cases did not reveal micrometastasis. The
overall accuracy is therefore 87.5% (7þ 5/16) with a negative
predictive value of 71.4% (5/7).
4. Discussion
To the best of our knowledge, this is the ﬁrst reported study
speciﬁcally assessing SLNB after NAC for IBC. We found a low IR
with a high – unacceptable – FNR even in selected patients without
palpable node after initial chemotherapy.
Recently published data support SLNB in the management of
locally advanced but non inﬂammatory breast cancer after NAC.
Reported IR and FNR vary from 83% to 98% and from 0%to 25%
respectively3,5,13,16–36 however its role in the management of IBC
is still unclear and ability of the SLNB to predict the status of the
remainder axillae after NAC for IBC is poorly documented. Stearns
V. et al.13 evaluated its potential beneﬁt in 8 cases concluding to
a low identiﬁcation rate (75%) and a high false-negative rate
(25%) and in the view of insufﬁcient data SLNB in IBC is not
recommended.12
IBC is the most aggressive form of breast cancer1 characterized
by a rapid progression, a high angioinvasive capability, an
aggressive behavior37 and a speciﬁc oncogenic pathway.38 Its
diagnosis still relies on clinical examination even if distinction
between ‘‘true’’ IBC and non inﬂammatory LABC with secondary
inﬂammatory characteristics can be difﬁcult. Epidemiological andative
ize
Tumor location Axillary status
before NAC
No. of positives nodes on axillary
dissection/total no. of nodes
External N1 9/16
internal N0 6/13
internal N2 7/11
N0 8/12
Table 3
Characteristics of patients’ false-negative SLNB after NAC.
Histology Initial tumor size No. of NAC cycles Preoperative tumor size Tumor location Axillary status before NAC No. of positives nodes on axillary
dissection/total no. of nodes
1 Invasive ductal 8 4 6 Central N1 1/10
2 Invasive ductal 8 4 6 Central N2 3/13
SLN: sentinel lymph node biopsy, NAC: neoadjuvant chemotherapy.
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a part of a continuum,39 but controversies still surround this
question.1 Incidence of IBC in Tunisia has been recently reassessed
by Boussen H. et al. and estimated around 7%6 higher than in
western countries.40 In Tunisia, there seems to be a speciﬁc
epidemiological context with a younger age at diagnosis42,43 but
a similar immunohistochemical proﬁles. (E-cadherin, ER, ERBB2,
MUC1 and Ki67).41
Many reasons may explain a low IR and a high FR in IBC, 1)
tumor emboli, inﬂammation or cellular material may impede the
dye ﬂow 2) larger tumorsmay havemultiple lymphatics drainage.16
3) Physiology of the lymphatic drainage may be altered by NAC
resulting in disruption and ﬁbrosis of lymph channels due to
apoptosis of tumor cells30 4) Lymph node may not respond equally
well after NAC with a possible regression in the ﬁrst node and
persistence of metastatic disease in some other axillary nodes.18
Some authors43,44 suggest that performance of SLN prior to NAC
may lead to more accurate information; however in a context of
IBC, we believe that this attitude is questionable.
Tausch C. et al.30 noticed that IR after NAC was higher with blue
dye than with radiocolloid because of smaller diameters allowing
better transport. In contrast, Mamounas et al.29 found the isotope
technique to have a signiﬁcant higher IR than the blue dye tech-
nique alone (88.9% vs. 78.1% respectively p¼ 0.03) and a trend
toward a higher false-negative rate when blue dye was used alone
(14% vs. 5% respectively p¼ 0.5).
Incidence of initial axillary histologic node involvement in IBC
ranges from 76 to 100%2,6; complete pathological response of
proven axillary metastases after NAC may be achieved in up to
40%.10,45,46 Interestingly, this response rate seems to be much
higher than the primary tumor itself.47
In the two cases of false-negative SLNB reported in our study,
initial nodal status were N1 and N2 and the tumor did not achieve
complete pathological response in both cases. Our population size
does not allow conclusions about clinical or pathological factors
inﬂuencing the false-negative rate after NAC and nodal status was
not determined by ﬁne-needle aspiration biopsy precluding
calculation of probability of non-SLN metastasis after NAC.49 Data
regarding the accuracy of SLNB with palpable nodes are conﬂict-
ing,29,48,50 the study by Mamounas et al.29 also concluded to
a higher accuracy rate for patients achieving complete pathological
response.
The present study includes the largest reported population of
IBC in whom SLNB was performed in a standard reproducible
technique. In our experience and as reported by others,22,51–53 we
feel that 10 min massage after injection of 2 ml of patent blue
volume at 2.5% concentration is the optimal method for SLNB using
blue dye.
Our study had limitations, we did not use combined technique
(isotope and dye) which is known to maximize success of SLNB.
Isotopes are not easily available in our practice and many authors
consider single agent use as appropriate: in a recent issue of the
Journal Rovera F. et al.54 reviewed literature and concluded that
‘‘Individual surgeons and institutions may utilize either radiocolloid or
blue dye alone with equal success after appropriate training and
experience’’ . Further more and as discussed above, Tausch C. et al.30noticed a higher IR after NAC with blue dye than with radiocolloid.
Finally, and most importantly in our opinion, the technique was
performed after achieving an acceptable detection and false-
negative rate by this method. Other limitations are inherent to any
single operator/institutional study and a median number of
retrieved SLN of 2.55 Finally patients at initial presentation with
initial palpable lymph node(s) were not cytologically documented
and studies have shown that clinical examination is not reliable
enough to precisely predict pathologic state.56 But we have to keep
in mind the relatively high degree of node pathological response
after NAC and the goal of our study which was to assess the IR and
FNR of SLNB in clinically negative axilla after NAC with a planned
immediate full axillary lymph node dissection. Nevertheless, we
think that our results are signiﬁcant of the available evidence on
accuracy of SLNB following NAC for IBC.
In the view of the current data, low incidence of inﬂammatory
breast cancer, high level of nodal involvement even after NAC, low
IR and high FNR of SLNB make this technique unsuitable in this
context if a systematic axillary clearance is not associated.
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